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Background: HIV-1 Pr55gag virus-like particles (VLPs) expressed by baculovirus in insect cells are considered to be a
very promising HIV-1 vaccine candidate, as they have been shown to elicit broad cellular immune responses when
tested in animals, particularly when used as a boost to DNA or BCG vaccines. However, it is important for the VLPs
to retain their structure for them to be fully functional and effective. The medium in which the VLPs are formulated
and the temperature at which they are stored are two important factors affecting their stability.
Findings: We describe the screening of 3 different readily available formulation media (sorbitol, sucrose and
trehalose) for their ability to stabilise HIV-1 Pr55gag VLPs during prolonged storage. Transmission electron
microscopy (TEM) was done on VLPs stored at two different concentrations of the media at three different
temperatures (4°C, –20°C and −70°C) over different time periods, and the appearance of the VLPs was compared.
VLPs stored in 15% trehalose at −70°C retained their original appearance the most effectively over a period of
12 months. VLPs stored in 5% trehalose, sorbitol or sucrose were not all intact even after 1 month storage at the
temperatures tested. In addition, we showed that VLPs stored under these conditions were able to be frozen and
re-thawed twice before showing changes in their appearance.
Conclusions: Although the inclusion of other analytical tools are essential to validate these preliminary findings,
storage in 15% trehalose at −70°C for 12 months is most effective in retaining VLP stability.
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In 2008, an estimated 1.9 million people in sub-Saharan
Africa were newly infected with HIV [1] and despite
advances in HIV vaccine research, a successful preventative
vaccine has still not been developed [2]. While many differ-
ent candidate types have been extensively investigated [3],
recombinant virus-like particles (VLPs) have shown signifi-
cant promise because they are non-replicating, safe [4,5]
and readily recognised by the immune system due to simi-
larity in structure to infectious virus particles. Their particu-
late nature also abrogates the use of adjuvants [6,7].
HIV-1 Gag polyprotein (Pr55gag) forms non-infectious
VLPs that are morphologically similar to HIV-1 particles
when expressed in isolation in insect cells [8]. We have* Correspondence: Ann.meyers@uct.ac.za
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reproduction in any medium, provided the orpreviously shown that these VLPs significantly boost im-
mune responses to a matched subtype C gag DNA in-
oculation in mice [9], as well as in baboons [10]. They
also boost a primary vaccination of baboons with recom-
binant BCG expressing a subtype C HIV-1 Gag [11] and
can be modified to display other proteins or epitopes, in
order to stimulate a broader immune response [6]. Ye
et al. [12] showed that SIV Gag-Env VLPs can boost
both DNA vaccine-induced cellular and humoral
responses in animals.
For VLPs to be used as vaccines, maintenance of their
integrity during purification and storage is very import-
ant, as a decrease in conformational stability would
affect their potency. As an example, storage temperature
adversely affects the conformation of VLPs as a result of
thermal instability [13,14]. The incorporation of protect-
ive molecules in the formulation buffer is thus often crit-
ical for VLP stabilisation and integrity. The cells of mosttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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known as osmolytes which stabilise and protect proteins,
in response to environmental stresses [15]. Polyols (in-
cluding glycerol, sucrose, sorbitol and trehalose) are
found in vascular plants, fungi and algae [16]: these are
natural, non-harmful substances and therefore suitable
for use in vaccine formulations as stabilisers. Preliminary
studies involving the use of trehalose, sucrose and gly-
cerol as stabilisers for Norwalk [17] and rotavirus VLPs
[18] and an influenza subunit vaccine [19] showed they
enhance the stability of both VLPs and proteins.
This research group continually generates HIV-1
VLPs for immunogenicity studies in animals, requiring
storage for varying lengths of time: accordingly, and in
the interests of reproducibility in our work, in this
study we evaluated the stability of HIV-1 Pr55gag
baculovirus-produced VLPs under different storage
conditions over a period of one year. The ability of 3
readily available osmolytes (trehalose, sorbitol and su-
crose) to maintain the protein in a non-aggregated state
without affecting its structure, potency and function at
specific temperatures was investigated. Two different
concentrations of osmolytes were selected (5% and 15%)
to cover the range over which stability of other VLPs
has been tested [17,18]. The number of freeze-thaw
cycles that a suitably formulated sample could with-
stand without degrading was also determined.
The HIV-1 Pr55gag sequence was the same as that
used for a South African HIV-1 subtype C vaccine
[20,21] and originated from isolate Du422 (GenBank ac-
cession AF544010). Human codon-optimised gag was
cloned into pFastBac (Invitrogen) under the polyhedron
promoter and expressed as described [9].
Gag VLPs were produced in Spodoptera frugiperda-
derived Sf9 cell suspension cultures (Invitrogen) by
infecting cells with baculovirus encoding gag at a MOI
between 2 and 10 PFU/mL. Cells were grown in SF900
serum-free insect cell medium (Gibco) supplemented
with 10 μg/ml gentamycin, at 270 rpm and 27°C.BA
Figure 1 Assessment of HIV-1 Pr55Gag VLPs using TEM. (A) Freshly pre
more VLPs have not retained their original appearance: VLPs retained in 1 ×
dense areas. (C) An example where all the VLPs (100%) have degraded: VLPVLPs were harvested from infected Sf9 culture super-
natant at 72 h post-infection by centrifugation (12 000 g,
1.5 h, Beckman SW32 Ti rotor), resuspended in 1 × PBS
pH 7.4 and sedimented through a 10–50% Optiprep™
step gradient at 12 000 g (Beckman SW32 Ti rotor) for
3 h at 4°C. The particle band with a density of 1.17 g/ml
[22] was syringe-extracted, resuspended in 1 × PBS, and
re-pelleted at 12 000 g for 1.5 h. Purified VLPs were
resuspended in 1 ml 1 × PBS.
Composition of purified Gag VLPs was confirmed by
anti-p24 western blot analysis (data not shown). Purified
VLPs were SDS-PAGE separated and electroblotted onto
nitrocellulose (NitroBond, Osmonics Inc.) for 1.5 h at
15 V. Membranes were probed with anti-p24 rabbit anti-
serum (1:10 000 dilution; ARP432, NISBC Centralised
Facility for AIDS reagents, MRC, UK), followed by anti-
rabbit alkaline phosphatase-conjugated secondary anti-
body (1:5 000 dilution; Sigma) and developed with
Nitroblue tetrazolium chloride/5-bromo-4-chloro-3-
indolyl phosphate (Roche).
Stock solutions (60%) of sucrose and sorbitol were
prepared in sterile, non-pyrogenic water for injection
(SABAX, Adcock Ingram) and filtered through a 0.2 μm
filter. Stock solutions (20% and 60%) of trehalose were
dissolved in sterile, non-pyrogenic water at 50°C and fil-
tered through a 0.45 μm filter. These were added to VLP
aliquots in 1 × PBS resulting in final concentrations of
5% and 15% respectively, and stored at 4°C, –20°C and
−70°C.
VLP preparations (between 1 and 2 per storage condi-
tion) were thawed and examined by TEM after 1, 3, 6
and 12 months of storage at 4°C, -20°C and −70°C. VLPs
were fixed onto carbon-coated copper grids (200 mesh),
stained with 2% uranyl acetate and visualized with a
LEO 912 microscope. TEM (Figure 1A) confirmed the
presence of Gag particles with uniform spherical shapes
of 100 to 120 nm in diameter, small dark centres and
dark outer membranes indicating uranyl acetate absorp-
tion, as similarly reported by others [6,9,22,23]. SomeC
pared VLPs resuspended in 1 × PBS. (B) An example where 50% or
PBS stored at −20°C after 1 month; the white arrows indicate electron
s retained in 5% trehalose at 4°C after 1 month. Scale bars = 500 nm.
Table 1 Summary of morphological observations of VLPs
under different storage conditions
Storage time (months)
Formulation medium Temperature 1 3 6 12
PBS 4°C √ × nd nd
-20°C ± × nd nd
-70°C ± × nd nd
5% Trehalose 4°C × nd nd nd
-20°C ± × nd nd
-70°C × nd nd nd
15% Trehalose 4°C √ × nd nd
-20°C √ √ √ √
-70°C √ √ √ √
5% Sucrose 4°C × nd nd nd
-20°C × nd nd nd
-70°C × nd nd nd
15% Sucrose 4°C √ × nd nd
-20°C √ ± × nd
-70 √ √ × nd
5% Sorbitol 4°C nd nd nd nd
-20°C ± × nd nd
-70°C ± × nd nd
15% Sorbitol 4°C 4°C nd nd nd
-20°C √ × nd nd
70°C √ ± × nd
√: the formulated VLP micrograph is identical to that of the fresh batch.
±: 50% or more of the formulated VLPs in the micrograph have changed shape.
×: 100% of the formulated VLPs have changed shape.
nd: not determined.
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aggregates were present, as previously seen in VLP pre-
parations used for animal testing [9-11]. Integrity of be-
tween 50 and 70 VLPs was graded according to the
average number of VLPs per three representative A    B C
Figure 2 Comparison of VLP morphology after storage in different os
1 × PBS. (B) VLPs after 12 months storage in 15% trehalose at −70°C. (C) VL
3 months storage in 15% sorbitol at −70°C. Scale bars = 500 nm.viewing frames at 10- to 15 000 ×magnification which
had the same appearance as when they were initially
purified. A change in appearance was regarded as a
change in particle size, uniform shape, or electron dense
area which indicates a change in stain accumulation and
hence a change in structure [23]. Changes in the VLP
core [22] could result in degradation or denaturation of
the CA and NC proteins that make up the Pr55gag poly-
proteins. This could cause breakdown of the VLP struc-
ture, disrupting the highly repetitive surface epitope
arrangement thereby altering the extent of the immune
response [24].
As shown in Table 1, VLPs were graded as stable if,
post storage, they looked morphologically and structur-
ally similar to freshly purified VLPs (√), semi-unstable if
preparations showed 50% or more degradation or alter-
ation of VLPs (±) (Figure 1B), and completely unstable if
preparations showed 100% degradation or alteration of
VLPs (Figure 1C).
Samples stored in 15% sucrose (Figure 2C) or trehal-
ose were the only ones that showed no difference in
VLP morphology after 3 months storage at −70°C com-
pared to their original appearance (Table 1). However,
VLPs in 15% sucrose displayed changes after 6 months
at −20°C or −70°C, whereas the 15% trehalose prepara-
tions remained stable at these temperatures. At
12 months in 15% trehalose, between 10% and 40% VLPs
stored at −20°C showed altered morphology (data not
shown), whereas no changes were observed at −70°C
(Figure 2B) compared to freshly made VLPs (Figure 2A).
This corroborates work of others who used trehalose to
stabilise Norwalk [17] and rotavirus VLPs [18] and influ-
enza vaccines [19]. VLPs stored in 5 and 15% sorbitol
were unstable after 3 and 6 months, respectively, when
stored at −20°C or −70°C (Figure 2D).
In general, lower concentrations of osmolytes (5%) did
not confer stability to VLPs at the three temperatures
tested after one month. Indeed, VLPs stored in the lowD 
molytes using TEM. (A) Freshly prepared VLPs resuspended in
Ps after 3 months storage in 15% sucrose at −70°C. (D) VLPs after
 A B C D 
Figure 3 VLPs stored in 15% trehalose at −70°C and subjected to different freeze-thaw cycles. A) 0 freeze-thaw cycles. B) 1 freeze-thaw
cycle after 1 month. C) 2 freeze thaw cycles after 3 months; white arrows indicate electron dense areas. D) 3 freeze-thaw cycles after 6 months.
Scale bars = 500 nm.
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those stored in PBS alone. While we did not investigate
this specifically, 30 years experience of working in the la-
boratory with purified plant viruses and VLPs indicates
that most preparations are more stable in buffers of
ionic strength above 0.05 – and the low-osmolyte pre-
parations were lower than this. Accordingly, we surmise
that both ionic and cryoprotective agents are necessary
for stabilisation. All higher percentage (15%) osmolytes
tested retained the original VLP appearance at 4°C for
one month, indicating they provided a provisional stabil-
isation medium.
Single aliquots of VLPs stored at −70°C in 15% trehal-
ose were subjected to 3 freeze-thaw cycles and analysed
for morphological changes using TEM. This was carried
out over a period of only 10 months due to time con-
straints with the sample being thawed on ice for 1 h
after 1, 3, 6 and 10 months (to corroborate results from
the osmolyte tests above). Results showed that VLPs can
withstand 2 freeze-thaw cycles, after which a change in
their appearance occurred (Figure 3). After the 2nd
freeze-thaw cycle, over 50% of the VLPs lost their uni-
form spherical shape (Figure 3C).
In conclusion, this preliminary investigation into VLP
storage and stability enabled us to compare the ability of
sucrose, trehalose and sorbitol to stabilise HIV-1 Pr55gag
VLPs at three different storage temperatures (4°C, -20°C
and −70°C) over the period of a year. Sorbitol and su-
crose were ineffective in retaining particle stability and
conformation, whereas 15% trehalose was highly effect-
ive in stabilising the VLPs for at least 1 year at −70°C. In
addition, VLPs stored under these conditions could
withstand up to 2 freeze-thaw cycles before exhibiting
changes in their uniformity.
Our report provides valuable baseline information on
exploring the long term-storage stabilisation of potential
HIV-1 VLP vaccine candidates. This method is now usedto store VLPs made for continued immunogenicity stud-
ies in our research group. Other techniques such as
asymmetrical flow field flow fractionation (AFFFF-
MALS) and electrospray differential mobility analysis
(ES-DMA) [25] may provide more information on the
VLP characteristics. In parallel, the ability of VLPs stored
under these conditions to stimulate an appropriate im-
mune response will need to be tested.
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